British Journal of Haematology最新文献_第2页

Flow cytometric identification of plasmacytoid dendritic cells in acute myeloid leukaemia: Challenges and practical considerations. 急性髓系白血病浆细胞样树突状细胞的流式细胞术鉴定：挑战和实际考虑。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-09-01 DOI: 10.1111/bjh.70807

Mariana S Vieira, Pietro B Belmonte, Natália A Marcondes, Raquel Q Vidal, Flavo B Fernandes, Liane N Rotta

引用次数: 0

Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study. 经典霍奇金淋巴瘤在治疗时期的总生存率提高：一项国家癌症数据库研究。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-09-01 DOI: 10.1111/bjh.70776

Julia Wang, Yajuan Gao, Spears M Grant, Steven R Hwang, Urshila Durani, Gita Thanarajasingam, Arushi Khurana, Jonas Paludo, Yucai Wang, Grzegorz S Nowakowski, Thomas M Habermann, Thomas E Witzig, Stephen M Ansell, Jithma P Abeykoon

引用次数: 0

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial. 单倍体造血干细胞移植治疗重度地中海贫血：一项IV期、开放标签、单中心试验

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-09-01 DOI: 10.1111/bjh.70819

Xiaoxuan Lai, Rongrong Liu, Hongwen Xiao, Lianjin Liu, Zhenbin Wei, Lingling Shi, Meiqing Wu, Zhongming Zhang, Yongrong Lai

{"title":"Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.","authors":"Xiaoxuan Lai, Rongrong Liu, Hongwen Xiao, Lianjin Liu, Zhenbin Wei, Lingling Shi, Meiqing Wu, Zhongming Zhang, Yongrong Lai","doi":"10.1111/bjh.70819","DOIUrl":"https://doi.org/10.1111/bjh.70819","url":null,"abstract":"We report the results of an open-label, single-centre phase 4 clinical trial evaluating haploidentical haematopoietic stem cell transplantation (Haplo-HSCT) in patients with transfusion-dependent thalassaemia (TDT). A total of 134 patients with TDT were enrolled; the median age was 8.7 years (interquartile range [IQR], 6.0-11.7 years; range, 3-20 years). All patients received a uniform conditioning regimen consisting of busulfan, cyclophosphamide, fludarabine and anti-thymocyte globulin (ATG). Graft-versus-host disease (GVHD) prophylaxis included methotrexate (MTX), mycophenolate mofetil (MMF) and tacrolimus. The primary end-point was 2-year overall survival (OS). Median follow-up is 23.4 months (IQR: 11.5-38.7; range: 6.1-81.5). The 2-year OS, event-free survival (EFS) and graft-versus-host disease-free, relapse-free survival (GRFS) rates were 93.4%, 92.6% and 77.5% respectively. The cumulative incidence rates of aGVHD, grade 2-4 aGVHD and grade 3-4 aGVHD were 47.8%, 30.9% and 12.5% respectively. Donor-specific antibodies (DSAs) and male-recipient/female-donor pairing were associated with inferior OS (p = 0.021; p = 0.010) and EFS (p = 0.040; p = 0.020). Hepatomegaly (≥5 cm) was associated with inferior OS (p = 0.037). Collectively, these findings support Haplo-HSCT as a key curative option for TDT patients in the absence of fully matched donors.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paediatric thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency and organomegaly syndrome: The United Kingdom experience. 儿童血小板减少、贫血、发热、网状蛋白纤维化、肾功能不全和器官肥大综合征：英国的经验。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-31 DOI: 10.1111/bjh.70821

Cortellazzo Wiel Luisa, Zeidan Ahmed, Pelech Nikki, Williamson Samantha Jayne, Haslam Kirsty, Wood Mark, Fiaccadori Valeria, Carpenter Ben, Payne Jeanette, Charles Biju, Satyen H Gohil, King David

引用次数: 0

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma. 伊鲁替尼与异基因造血干细胞移植治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-31 DOI: 10.1111/bjh.70803

Farrukh T Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani

引用次数: 0

An economic evaluation of integrating primary care for depression management during transition in sickle cell disease. 镰状细胞病过渡期抑郁症综合初级保健管理的经济评价

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-31 DOI: 10.1111/bjh.70814

Robert M Cronin, Nives Quaye, Kristina Landes, Roberta Azbell, Sherraine Della-Moretta, Regina D Crawford, Susan Creary, Patrick M Schnell, Chyongchiou J Lin

引用次数: 0

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. 伊唑唑米、泊马度胺和地塞米松治疗复发或难治性多发性骨髓瘤的前瞻性IV期研究

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-30 DOI: 10.1111/bjh.70806

Runfeng Zhang, Hong Yu, Miao Chen, Xiaoqi Qin, Jie Xiao, Yun Leng, Mingzhe Zhao, Jie Yu, Chunjie Qin, Xiuju Wang, Jingcheng Zhang, Wei Wang, Wenming Chen, Yanping Ma, Rong Fu, Junling Zhuang

引用次数: 0

Older and frail patients with multiple myeloma treated with bispecific antibodies: A systematic review and meta-analysis. 双特异性抗体治疗老年虚弱多发性骨髓瘤患者：一项系统回顾和荟萃分析。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-30 DOI: 10.1111/bjh.70804

Hafsa M Gundroo, Elham Nasrollahi, Becky Alford, Binod Dhakal, Ravi Narra, Anita D'Souza, Rahul Mhaskar, Othman Salim Akhtar

引用次数: 0

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma. SAKK 35/14随机试验利妥昔单抗联合或不联合依鲁替尼治疗未经治疗的滤泡性淋巴瘤患者。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-30 DOI: 10.1111/bjh.70801

Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann-Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad

{"title":"SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.","authors":"Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann-Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad","doi":"10.1111/bjh.70801","DOIUrl":"https://doi.org/10.1111/bjh.70801","url":null,"abstract":"The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ibrutinib (560 mg daily for 24 months, arm B) in patients with advanced follicular lymphoma in need of systemic therapy. The primary end-point, complete remission (CR) rate at 24 months, was 36% in arm A and 40% in arm B, with no statistically significant difference. Three-year progression-free survival (PFS) was 36% in arm A and 45% in arm B, with a hazard ratio of 0.64 (p = 0.057). Three-year overall survival was about 96% in both arms. A higher percentage of patients in arm B experienced grade ≥3 adverse events, but they were manageable. No toxic deaths were observed. Although the primary end-point (CR rate at 24 months) was not met, a trend towards improved PFS with ibrutinib plus rituximab observed at the prespecified significance level of 0.1 may indicate a potential clinical benefit.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy. 匹托鲁替尼治疗Richter综合征：意大利冠名患者项目的结果

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-30 DOI: 10.1111/bjh.70805

Isacco Ferrarini, Daniela Estefania Banegas, Andrea Bernardelli, Alessia Moioli, Francesca Maria Quaglia, Ester Lovato, Anna Maria Frustaci, Massimiliano Postorino, Davide Facchinelli, Monica Tani, Francesca Cibien, Chandrakala Toldo, Elisa Lucchini, Roberto Marasca, Marzia Varettoni, Chiara Rusconi, Lucia Farina, Andrea Visentin, Riccardo Moia, Carlo Visco

引用次数: 0